Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
12 sept. 2019 16h20 HE
|
Ascendis Pharma A/S
– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
17 sept. 2018 16h10 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...